BioSpecifics Technologies (BSTC) Given News Sentiment Rating of 0.06

Media headlines about BioSpecifics Technologies (NASDAQ:BSTC) have been trending somewhat positive on Thursday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioSpecifics Technologies earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.058400172777 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of NASDAQ:BSTC traded up $0.06 during trading on Thursday, hitting $44.15. 21,422 shares of the company traded hands, compared to its average volume of 27,886. The firm has a market capitalization of $316.33, a PE ratio of 25.97 and a beta of 1.43. BioSpecifics Technologies has a one year low of $38.05 and a one year high of $58.79.

How to Become a New Pot Stock Millionaire

Several analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating on shares of BioSpecifics Technologies in a report on Tuesday, December 26th. Zacks Investment Research lowered BioSpecifics Technologies from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 27th. Finally, BidaskClub raised BioSpecifics Technologies from a “strong sell” rating to a “sell” rating in a report on Saturday, March 24th.

ILLEGAL ACTIVITY WARNING: “BioSpecifics Technologies (BSTC) Given News Sentiment Rating of 0.06” was originally published by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://baseballnewssource.com/2018/04/05/biospecifics-technologies-bstc-getting-somewhat-positive-news-coverage-study-finds/2028396.html.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Insider Buying and Selling by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.